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Abstract
Metallothioneins (MTs) are excellent candidate genes for Inflammatory Bowel Disease (IBD) and have previously
been shown to have altered expression in both animal and human studies of IBD. This is the first study to examine
genetic variants within the MT genes and aims to determine whether such genetic variants have an important role
in this disease. 28 tag SNPs in genes MT1 (subtypes A, B, E, F, G, H, M, X), MT2, MT3 and MT4 were selected for
genotyping in a well-characterized New Zealand dataset consisting of 406 patients with Crohn’s Disease and 638
controls. We did not find any evidence of association for MT genetic variation with CD. The lack of association
indicates that genetic variants in the MT genes do not play a significant role in predisposing to CD in the New
Zealand population.
Keywords: Crohn’s disease, Metallothioneins, genetic association
Background
Inflammatory bowel disease (IBD) is a disorder charac-
terised by chronic, relapsing inflammation of the gastro-
intestinal tract and is characterized by the presence of
an increased level of reactive oxygen species in the
mucosal intestinal tissue as well as oxidative DNA and
protein damage, defective host-microbe interactions,
immune cell infiltration, and disturbed T cell apoptosis.
Metallothioneins (MTs) are able to affect all of these
processes, making them good candidates for IBD. MTs
are ubiquitous metal-binding proteins that have been
highly conserved throughout evolution and are rapidly
upregulated in response to an inflammatory stimulus.
There are four main isoforms expressed in humans:
MT1 (subtypes A, B, E, F, G, H, M, X), MT2, MT3 and
MT4. These genes cluster together on a single locus on
chromosome 16 (16q13) [1].
Support for the hypothesis of MTs playing an
important role in the pathogenesis of IBD has come
from various reports demonstrating altered MT
expression in IBD. However these reports have been
contradictory (for a summary see Waeytens et al.,
2009 [2]) with some studies reporting MT
upregulation in IBD [3,4] and others demonstrating a
downregulation [5-11]. The inconsistencies between
the various studies may be explained by differences in
patients samples such as age, medication, disease
activity, zinc status, as well as from where the tissue
was sampled (ileum or colon).
Whilst there have been several studies investigating
expression of MTs in IBD, there have been no studies
published to date investigating genetic variants in MTs
and IBD. The aim of this study is to identify SNPs
across these genes and to genotype these in a well-char-
acterised Caucasian New Zealand IBD dataset and to
examine the results for evidence of genetic association
between any of the MT genes and IBD.
Methods
Samples
A total of 1044 subjects from New Zealand were
included in the study: 406 CD patients and 638 age and
sex matched controls. All participants self-reported Eur-
opean ancestry.
Clinical records were analysed to confirm diagnosis,
and IBD status was defined using standard diagnostic
criteria [12]. Cases were phenotyped according to the
Montreal Classification systems. Clinical characteristics
of the CD patients are shown in table 1. * Correspondence: ang.morgan@auckland.ac.nz
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blood or a buccal swab for DNA extraction and geno-
typing, and DNA was extracted from the blood/buccal
samples using Qiagen’s DNA extraction kit and follow-
ing the manufacturer’s instructions.
The study was conducted under ethical protocol
MEC/04/12/011, authorised through the New Zealand
Multi-Region Human Ethics Committee. All study sub-
jects gave informed consent.
Snp selection
Tag SNPs in genes MT1 (subtypes A, B, E, F, G, H, M,
X), MT2, MT3 and MT4 were selected using Hapmap
release 28, and the tagger functionality within Haploview
with pairwise tagging to identify SNPs using an r
2 >0 . 8
and a minor allele frequency > 5%. As a result 28 tag
SNPs were selected for genotyping.
Genotyping
Genotyping was performed with the MassARRAY and
iPlex systems of the Sequenom genotyping platform
(Sequenom, San Diego, CA), which uses the MALDI-
TOF primer extension assay [13,14], according to manu-
facturers’ recommendations.
Assays were optimized in 24 samples consisting of 20
reference Centre d’Etude du Polymorphisme Humain
(CEPH) samples and 4 blanks.
All sample plates contained cases, controls, blanks,
CEPH and duplicate samples. Quality control measures
included independent double genotyping and, where
available, comparison of our CEPH genotypes to those
in the Hapmap database http://www.hapmap.org.
Statistical analysis
SNPs were tested for deviation from HWE in both cases
and controls using a chi-square goodness-of-fit test. To
determine if there were differences between cases and
controls, genotype and allele frequencies for each SNP
were analyzed by 2 × 3 and 2 × 2 Chi-square tables
respectively
Genotype and phenotype associations were assessed by
comparing allele frequencies between controls and
patient subgroups defined using the clinical characteris-
tics. These analyses were carried out using R (R: A lan-
guage and environment for statistical computing, R
Foundation for Statistical Computing, Vienna, Austria.
ISBN 3-900051-07-0, URL http://www.R-project.org/)
and SAS (V9.1 SAS Institute., Cary, NC, USA).
To determine linkage disequilibrium (LD) between
SNPs and to define haplotype blocks, we uploaded our
data into Haploview [15]. Haplotype blocks were defined
using the default algorithm which uses confidence inter-
vals [16]. Haplotype analysis was carried using HAPLO.
SCORE in R to test for association of these haplotypes
with CD.
For all analyses we considered a p values less than
0.05 to indicate statistical significance.
The false discovery rate (FDR) was used to correct for
multiple testing [17,18].
Results and discussion
Three SNPs did not fit into the Sequenom multiplexes:
rs1827210 (MT1M), rs11076161 (MT1A), rs2298846
(MT1G). Two SNPs failed to be successfully geno-
typed: rs1827208 (MT1M) and rs12448654 (MT1G).
One SNP was out of HWE in the control samples and
so was excluded from further analysis: rs12051311
(MT1B). Thus there were 22 SNPs with genotype data
for analysis. Genotype and allele counts/frequencies
and p-values are shown in table 2. One SNP rs4784708
(MT1H) was found to be associated with CD (genoty-
pic p = 0.0197, allelic p = 0.016) but after applying
multiple testing correction using FDR the result is no
longer statistically significant. Thus we can conclude
that individual SNPs in the MT genes are not asso-
ciated with CD.
Calculations of statistical power using PS 2.1.31 [19]
show that using our case-control sample set although we
have good power to detect an odds ratio of 1.3 for com-
mon SNPs (for example for a SNP with MAF 0.42 (e.g.,
rs11644094) we have 86.5% power) the power is consid-
erably lower for SNPs with low MAF. For example for a
SNP with MAF of 0.02 (e.g., rs9936741) we have 16.1%
Table 1 Summary of clinical data of CD patients.
CD
Gender F 265 (65.6)
M 139 (34.4)
Age at Diagnosis < 17 46 (12.6)
17 to 40 257 (70.2)
40 < 63 (17.2)
CD Behaviour Inflammatory 201 (55.1)
Stricturing 118 (32.3)
Penetrating 46 (12.6)
CD Location Ileal 136 (37.2)
Colonic 119 (32.5)
Ileocolonic 111 (30.3)
Bowel resection N 270 (66.7)
Y 135 (33.3)
Other IBD family N 330 (89.7)
Y 38 (10.3)
EIM N 301 (81.8)
Y 67 (18.2)
Perianal disease N 329 (85.7)
Y 55 (14.3)
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SNP Location gene CASE CONTROL p CASE CONTROL p
rs182221 56, 599, 221 MT4 G/G 262 (0.66) 398 (0.64) 0.87 G 646 (0.81) 995 (0.80) 0.72
C/G 122 (0.31) 199 (0.32) C 154 (0.19) 247 (0.20)
C/C 16 (0.04) 24 (0.04)
rs666636 56, 601, 720 MT4 G/G 386 (0.95) 599 (0.95) 0.70* G 791 (0.98) 1229 (0.97) 0.55
A/G 19 (0.05) 31 (0.05) A 19 (0.02) 35 (0.03)
A/A 0 (0.00) 2 (0.00)
rs666647 56, 601, 722 MT4 C/C 386 (0.95) 605 (0.95) 0.73* C 791 (0.98) 1241 (0.97) 0.58
C/T 19 (0.05) 31 (0.05) T 19 (0.02) 35 (0.03)
T/T 0 (0.00) 2 (0.00)
rs669293 56, 602, 352 MT4 T/T 293 (0.73) 428 (0.67) 0.16 T 686 (0.85) 1039 (0.82) 0.051
C/T 100 (0.25) 283 (0.29) C 120 (0.15) 231 (0.18)
C/C 10 (0.02) 24 (0.04)
rs762604 56, 602, 671 MT4 C/C 183 (0.45) 302 (0.48) 0.18 C 538 (0.67) 878 (0.70) 0.15
C/T 172 (0.43) 274 (0.44) T 268 (0.33) 380 (0.30)
T/T 48 (0.12) 53 (0.08)
rs11643815 56, 602, 798 MT4 G/G 307 (0.76) 482 (0.76) 0.53 G 700 (0.86) 1102 (0.87) 0.61
A/G 86 (0.21) 138 (0.22) A 110 (0.14) 162 (0.13)
A/A 12 (0.03) 12 (0.02)
rs11644094 56, 624, 079 MT3 A/A 134 (0.34) 220 (0.35) 0.90 A 460 (0.58) 736 (0.58) 0.79
A/G 192 (0.48) 295 (0.47) G 338 (0.42) 527 (0.42)
G/G 73 (0.18) 116 (0.18)
rs10636 56, 643, 343 MT2A G/G 228 (0.57) 358 (0.57) 0.66 G 598 (0.74) 946 (0.75) 0.67
C/G 142 (0.35) 230 (0.37) C 206 (0.26) 312 (0.25)
C/C 32 (0.08) 41 (0.07)
rs2070836 56, 660, 120 MT1E G/G 346 (0.85) 530 (0.84) 0.56 G 746 (0.92) 1156 (0.92) 0.69
C/G 54 (0.13) 96 (0.15) C 64 (0.08) 106 (0.08)
C/C 5 (0.01) 5 (0.01)
rs708274 56, 660, 906 MT1E G/G 310 (0.78) 482 (0.77) 0.22 G 701 (0.88) 1100 (0.88) 0.80
G/T 81 (0.20) 136 (0.22) T 95 (0.12) 144 (0.12)
T/T 7 (0.02) 4 (0.01)
rs2270836 56, 667, 614 MT1M C/C 169 (0.42) 231 (0.37) 0.19 C 516 (0.64) 764 (0.61) 0.083
C/T 178 (0.44) 302 (0.48) T 286 (0.36) 498 (0.39)
T/T 54 (0.13) 98 (0.16)
rs9936741 56, 667, 785 MT1M T/T 387 (0.96) 610 (0.95) 0.94* T 792 (0.98) 1249 (0.98) 0.94
C/T 18 (0.04) 29 (0.05) C 18 (0.02) 29 (0.02)
C/C 0 (0.00) 0 (0.00)
rs7190725 56, 673, 290 MT1A G/G 308 (0.76) 483 (0.76) 0.99 G 706 (0.87) 1109 (0.87) 0.94
G/T 90 (0.22) 143 (0.22) T 104 (0.13) 165 (0.13)
T/T 7 (0.02) 11 (0.02)
rs964372 56, 686, 030 MT1B G/G 317 (0.78) 514 (0.81) 0.65 G 714 (0.88) 1142 (0.89) 0.34
C/G 80 (0.20) 114 (0.18) C 96 (0.12) 134 (0.11)
C/C 8 (0.02) 10 (0.02)
rs2070839 56, 686, 242 MT1B C/C 152 (0.38) 256 (0.40) 0.17 C 503 (0.63) 792 (0.62) 0.89
C/T 199 (0.50) 280 (0.44) T 301 (0.37) 480 (0.38)
T/T 51 (0.13) 100 (0.16)
rs2291956 56, 692, 218 MT1F C/C 308 (0.76) 481 (0.76) 0.97 C 705(0.87) 1104 (0.87) 0.97
C/T 89 (0.22) 142 (0.22) T 103 (0.13) 162 (0.13)
T/T 7 (0.02) 10 (0.02)
rs2298847 56, 701, 294 MT1G T/T 310 (0.77) 495 (0.79) 0.28 T 709 (0.88) 1107 (0.89) 0.58
A/T 89 (0.22) 117 (0.19) A 99 (0.12) 143 (0.11)
A/A 5 (0.01) 13 (0.02)
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with CD cannot be entirely ruled out as it may simply be
that we do not have the power in our study to detect
such an association. A replication study in a larger sam-
ple set is encouraged.
There are 5 haplotype blocks in this region (Figure 1)
but examining the different haplotypes we did not find
any associations with CD (data not shown but available
on request).
We also undertook a phenotype analysis and after
multiple testing corrections none of the SNPs were
associated with any of the different clinical characteris-
tics of CD (data not shown but available on request).
This is the first study to investigate genetic association
with MT SNPs and IBD. In summary although MT
genes are good candidates for CD, the present study
failed to detect any significant associations. The lack of
association indicates that genetic variants in the MT
genes do not play a significant role in predisposing to
CD in the New Zealand population.
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